Loading...
Loading...
RNLX| Name | Value |
|---|---|
| Revenues | 459.0K |
| Cost of Revenue | 502.0K |
| Gross Profit | -43.0K |
| Operating Expense | 8,846.0K |
| Operating I/L | -8,889.0K |
| Other Income/Expense | -1,265.0K |
| Interest Income | 0.0K |
| Pretax | -10,154.0K |
| Income Tax Expense | 0.0K |
| Net Income/Loss | -10,154.0K |
Renalytix Plc develops artificial intelligence-enabled in vitro diagnostic solutions for kidney diseases. The company's flagship product, KidneyIntelX, utilizes an AI algorithm to analyze blood-based biomarkers, genetics, and patient data to generate personalized risk scores for kidney disease diagnosis, prognosis, and patient stratification for drug trials. Renalytix has license and partnership agreements with leading healthcare institutions to develop and commercialize AI-based diagnostic products for kidney disease and SARS-CoV-2 antibody detection. The company generates revenue through the sale of its diagnostic platforms and through collaborative research and development initiatives with healthcare partners.
